Mondrian Investment Partners LTD maintained its stake in shares of Sanofi (NYSE:SNY) during the second quarter, Holdings Channel reports. The institutional investor owned 1,250,842 shares of the company’s stock at the end of the second quarter. Sanofi comprises about 1.7% of Mondrian Investment Partners LTD’s holdings, making the stock its 15th largest position. Mondrian Investment Partners LTD’s holdings in Sanofi were worth $59,928,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Harbour Capital Advisors LLC acquired a new stake in shares of Sanofi during the first quarter worth approximately $113,000. Eagle Ridge Investment Management acquired a new stake in shares of Sanofi during the second quarter worth approximately $160,000. Nelson Van Denburg & Campbell Wealth Management Group LLC boosted its stake in shares of Sanofi by 6,188.3% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 3,773 shares of the company’s stock worth $171,000 after buying an additional 3,713 shares during the last quarter. BLB&B Advisors LLC acquired a new stake in shares of Sanofi during the first quarter worth approximately $202,000. Finally, Huntington National Bank boosted its stake in shares of Sanofi by 3.4% in the first quarter. Huntington National Bank now owns 4,455 shares of the company’s stock worth $202,000 after buying an additional 147 shares during the last quarter. Institutional investors own 9.96% of the company’s stock.

Sanofi (NYSE SNY) opened at 47.41 on Friday. Sanofi has a one year low of $36.81 and a one year high of $50.24. The stock has a 50 day moving average of $48.05 and a 200-day moving average of $46.06. The company has a market cap of $119.07 billion, a price-to-earnings ratio of 11.20 and a beta of 0.88.

Sanofi (NYSE:SNY) last released its quarterly earnings results on Monday, July 31st. The company reported $0.74 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.74. The company had revenue of $8.66 billion for the quarter, compared to the consensus estimate of $8.71 billion. Sanofi had a net margin of 25.89% and a return on equity of 25.34%. The business’s revenue was down 2.3% on a year-over-year basis. On average, equities analysts predict that Sanofi will post $3.26 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece was posted by Daily Political and is owned by of Daily Political. If you are reading this piece on another website, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this piece can be accessed at https://www.dailypolitical.com/2017/08/11/mondrian-investment-partners-ltd-maintains-position-in-sanofi-nysesny.html.

A number of analysts recently commented on SNY shares. TheStreet upgraded shares of Sanofi from a “c+” rating to a “b-” rating in a research note on Monday, April 24th. BidaskClub upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. Argus increased their target price on shares of Sanofi from $50.00 to $55.00 and gave the stock a “buy” rating in a research note on Friday, June 9th. Zacks Investment Research upgraded shares of Sanofi from a “hold” rating to a “buy” rating and set a $55.00 target price on the stock in a research note on Friday, June 2nd. Finally, Berenberg Bank cut shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, May 11th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and five have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $63.75.

Sanofi Company Profile

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NYSE:SNY).

Institutional Ownership by Quarter for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.